# SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease

> **NCT05332678** · PHASE2 · WITHDRAWN · sponsor: **Seelos Therapeutics, Inc.**

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** SLS-005 - Once Weekly
- **DRUG:** SLS-005 - Twice Weekly

## Key facts

- **NCT ID:** NCT05332678
- **Lead sponsor:** Seelos Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-03-03
- **Primary completion:** 2023-04-10
- **Final completion:** 2023-04-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2023-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05332678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05332678, "SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05332678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*